Filing Summary
Registrant: Jupiter Wellness, Inc. The request metadata identifies BONK, Inc., but the filing is for Jupiter Wellness, Inc. (Nasdaq: JUPW; warrants: JUPWW).
Form 8-K date: July 12, 2021, with the report signed and a related press release issued July 13, 2021.
Business Context and Material Agreement
On July 12, 2021, Jupiter Wellness entered into a clinical trial research agreement with Applied Biology, s.r.o., a Czech company. Applied Biology will design, manage, and conduct a head-to-head study comparing JW-101 with EUCRISA (crisaborole ointment 2%) for the treatment of eczema.
- Jupiter Wellness will sponsor the study.
- The projected budget for Applied Biology’s research activities is $1,088,010.
- The agreement became effective July 12, 2021 and continues until the parties complete their obligations.
- Portions of Appendix A were redacted and are subject to a confidential-treatment request under Rule 24b-2.
Financial Metrics and Liquidity
The filing does not provide revenue, earnings, cash flow, margins, debt, cash balances, liquidity measures, or other financial statement information. The disclosed $1,088,010 is a projected clinical-study budget, not reported revenue or expense for the period.
Changes Versus Prior Period
The filing does not provide a prior-period comparison. It discloses the execution of a new clinical trial agreement but does not quantify its impact on historical or forecast financial results.
Guidance, Outlook, Risks, and Unusual Items
- The filing does not provide formal financial guidance or an expected completion date for the study.
- The study is intended to compare JW-101 with an established eczema treatment; the filing does not report clinical results, efficacy, safety findings, regulatory status, or commercialization prospects.
- The study creates a planned research obligation of $1,088,010, subject to the terms of the agreement.
- A July 13 press release concerning a “License Agreement” was furnished as Exhibit 99.1, but the supplied filing text does not provide the license terms or related financial impact.
Key Facts to Verify
- Confirm that the filing relates to Jupiter Wellness, Inc., not BONK, Inc.
- Review Exhibit 10.1 for payment terms, milestones, termination provisions, and the complete scope of the clinical trial.
- Review the redacted Appendix A and any subsequent SEC action regarding confidential treatment.
- Review Exhibit 99.1 for the referenced license agreement and determine whether it creates additional obligations, rights, or dilution.
- Verify subsequent filings for study progress, costs incurred, clinical results, regulatory developments, and liquidity effects.